From football fields to basketball courts, table tennis halls to motocross tracks, families are investing time, money and ...
The Cardiac Arrest Treatment Market is witnessing substantial growth due to the increasing prevalence of cardiovascular diseases, rising awareness about emergency cardiac care, and advancements in ...
Zacks Investment Research on MSN
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $2.18 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to a loss of $5.12 per share a year ago. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback